Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Rockwell Medical (RMTI) EBITDA Margin (2016 - 2025)

Rockwell Medical's EBITDA Margin history spans 16 years, with the latest figure at 2.17% for Q4 2025.

  • For Q4 2025, EBITDA Margin fell 7.0% year-over-year to 2.17%; the TTM value through Dec 2025 reached 6.77%, down 737.0%, while the annual FY2025 figure was 6.77%, 737.0% down from the prior year.
  • EBITDA Margin reached 2.17% in Q4 2025 per RMTI's latest filing, up from 9.95% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 6.84% in Q3 2024 to a low of 54.52% in Q4 2021.
  • Average EBITDA Margin over 5 years is 17.58%, with a median of 9.17% recorded in 2025.
  • Peak YoY movement for EBITDA Margin: surged 4434bps in 2022, then crashed -1678bps in 2025.
  • A 5-year view of EBITDA Margin shows it stood at 54.52% in 2021, then skyrocketed by 81bps to 10.18% in 2022, then skyrocketed by 76bps to 2.48% in 2023, then rose by 15bps to 2.1% in 2024, then dropped by -3bps to 2.17% in 2025.
  • Per Business Quant, the three most recent readings for RMTI's EBITDA Margin are 2.17% (Q4 2025), 9.95% (Q3 2025), and 8.39% (Q2 2025).